StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) stock

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.48−0.23 (-0.22%)

Close on Nov 18, 2026Market cap $180.79BP/E 33.6Yield 2.30%

Abbott Laboratories revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Abbott Laboratories's revenue for the twelve months ending Jun 30, 2026 was $46.59B, up 8.1% year over year. For fiscal 2025 it was $44.33B, up 5.7% from the year before. Over ten years it grew 8.1% a year on average. The highest annual figure on record is $44.33B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$44.33B+5.7%
FY2024Dec 31, 2024$41.95B+4.6%
FY2023Dec 31, 2023$40.11B-8.1%
FY2022Dec 31, 2022$43.65B+1.3%
FY2021Dec 31, 2021$43.08B+24.5%
FY2020Dec 31, 2020$34.61B+8.5%
FY2019Dec 31, 2019$31.90B+4.3%
FY2018Dec 31, 2018$30.58B+11.6%
FY2017Dec 31, 2017$27.39B+31.3%
FY2016Dec 31, 2016$20.85B+2.2%
FY2015Dec 31, 2015$20.41B+0.8%
FY2014Dec 31, 2014$20.25B+3.0%
FY2013Dec 31, 2013$19.66B+3.2%
FY2012Dec 31, 2012$19.05B-11.0%
FY2011Dec 31, 2011$21.41B-39.1%
FY2010Dec 31, 2010$35.17B+14.3%
FY2009Dec 31, 2009$30.76B+4.2%
FY2008Dec 31, 2008$29.53B+13.9%
FY2007Dec 31, 2007$25.91B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.59B+13.0%
Q1 FY2026Mar 31, 2026$11.16B+7.8%
Q4 FY2025Dec 31, 2025$11.46B+4.4%
Q3 FY2025Sep 30, 2025$11.37B+6.9%
Q2 FY2025Jun 30, 2025$11.14B+7.4%
Q1 FY2025Mar 31, 2025$10.36B+4.0%
Q4 FY2024Dec 31, 2024$10.97B+7.2%
Q3 FY2024Sep 30, 2024$10.64B+4.9%
Q2 FY2024Jun 30, 2024$10.38B+4.0%
Q1 FY2024Mar 31, 2024$9.96B+2.2%
Q4 FY2023Dec 31, 2023$10.24B+1.5%
Q3 FY2023Sep 30, 2023$10.14B-2.6%
Q2 FY2023Jun 30, 2023$9.98B-11.4%
Q1 FY2023Mar 31, 2023$9.75B-18.1%
Q4 FY2022Dec 31, 2022$10.09B-12.0%
Q3 FY2022Sep 30, 2022$10.41B-4.7%
Q2 FY2022Jun 30, 2022$11.26B+10.1%
Q1 FY2022Mar 31, 2022$11.90B+13.8%
Q4 FY2021Dec 31, 2021$11.47B+7.2%
Q3 FY2021Sep 30, 2021$10.93B+23.4%
Q2 FY2021Jun 30, 2021$10.22B+39.5%
Q1 FY2021Mar 31, 2021$10.46B+35.3%
Q4 FY2020Dec 31, 2020$10.70B+28.7%
Q3 FY2020Sep 30, 2020$8.85B+9.6%
Q2 FY2020Jun 30, 2020$7.33B-8.2%
Q1 FY2020Mar 31, 2020$7.73B+2.5%
Q4 FY2019Dec 31, 2019$8.31B+7.1%
Q3 FY2019Sep 30, 2019$8.08B+5.5%
Q2 FY2019Jun 30, 2019$7.98B+2.7%
Q1 FY2019Mar 31, 2019$7.54B+2.0%
Q4 FY2018Dec 31, 2018$7.77B+2.3%
Q3 FY2018Sep 30, 2018$7.66B+12.1%
Q2 FY2018Jun 30, 2018$7.77B+17.0%
Q1 FY2018Mar 31, 2018$7.39B+16.7%
Q4 FY2017Dec 31, 2017$7.59B+42.3%
Q3 FY2017Sep 30, 2017$6.83B+28.8%
Q2 FY2017Jun 30, 2017$6.64B–
Q1 FY2017Mar 31, 2017$6.34B–
Q4 FY2016Dec 31, 2016$5.33B–
Q3 FY2016Sep 30, 2016$5.30B–

More Abbott Laboratories figures

See a number that looks wrong?